Supplemental Figure 1A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Year: 2023
Type: supplementary-materials
Abstract: Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plots are color-coded by (A) best overall response (PR, SD, PD), (B) cohort (1-6), and (C) tumor type (melanoma, RCC, NSCLC). The majority of patients who experienced disease progression on the study had progression in non-target lesions, as denoted by as asterisk (*), and therefore the percent change in tumor from baseline by RECIST is less than the 20% disease progression threshold for multiple patients who had PD.
Authors: Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361890052